TP53 and liver cancer: In addition, USP22 can promote hypoxia-induced generation of liver cancer stem cells through the HIF1α/USP22 positive feedback loop after p53 inactivation, and lipoprotein complexes targeting USP22 can inhibit the growth of liver cancer cells and enhance sorafenib sensitivity (77).